Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.74 USD | -0.36% | 0.00% | +9.60% |
Jun. 03 | Oncocyte Corporation Announces Promising Results in A Phase 2 Clinical Trial | CI |
May. 30 | Oncocyte Corporation Announces Favorable Oncocyte Vitgraft Kidney Study Results | CI |
Financials (USD)
Sales 2024 * | 1.51M | Sales 2025 * | 4.83M | Capitalization | 36.62M |
---|---|---|---|---|---|
Net income 2024 * | -26M | Net income 2025 * | -20M | EV / Sales 2024 * | 24.3 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.58 x |
P/E ratio 2024 * |
-0.99
x | P/E ratio 2025 * |
-1.61
x | Employees | 45 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.2% |
Latest transcript on OncoCyte Corporation
1 day | -0.36% | ||
1 month | -0.72% | ||
3 months | -8.67% | ||
6 months | -28.65% | ||
Current year | +9.60% |
Managers | Title | Age | Since |
---|---|---|---|
Joshua Riggs
CEO | Chief Executive Officer | 42 | 20-07-31 |
James Liu
DFI | Director of Finance/CFO | 29 | 21-06-30 |
Yuh-Min Chiang
CTO | Chief Tech/Sci/R&D Officer | - | 21-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Last
BRD | Director/Board Member | 64 | 15-12-22 |
Louis Silverman
BRD | Director/Board Member | 65 | 22-11-29 |
Andy Arno
CHM | Chairman | 64 | 15-05-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 2.74 | -0.36% | 6,753 |
24-06-06 | 2.75 | +3.77% | 14,693 |
24-06-05 | 2.65 | 0.00% | 10,030 |
24-06-04 | 2.65 | -1.85% | 24,011 |
24-06-03 | 2.7 | -1.46% | 60,547 |
Delayed Quote Nasdaq, June 07, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.60% | 36.62M | |
-41.97% | 7.92B | |
+5.99% | 3.51B | |
-4.31% | 2.18B | |
-21.69% | 1.97B | |
-24.94% | 1.58B | |
+31.45% | 1.14B | |
+26.75% | 792M | |
-9.83% | 690M | |
-26.33% | 532M |
- Stock Market
- Equities
- OCX Stock